Home
Network
Vision and Mission
Steering Committee
Members
Meetings
Join us
Training
Advocate
Establish
Strengthen
Evaluate
Media Center
News
SYSVAC
About
Registry
E-learning course
Events
Sign in
*
*
Home
Media Center
Media Center
Type of publications
NITAG documentation
SAGE documentation
Regions
Americas
Europe
Countries
Argentina
Canada
France
United States of America
Diseases
(-)
Dengue
(-)
Diphtheria
Ebola
Hepatitis A
Hepatitis B
Herpes zoster
Human papillomavirus
Influenza
Japanese encephalitis
Measles
Meningitis
Mumps
Pertussis
Poliomyelitis
Rabies
Rotavirus
Rubella
Tetanus
Tuberculosis
Typhoid
Yellow fever
Publication date
(-)
2018
2020
2019
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2006
2003
2002
2000
1997
CoNaIn meeting minutes - March 2018
Agenda & Minutes
Download:
ES
Published: 2018
Author: CoNaIn
Minutes of the CTV meeting - November 6th 2018
meeting minutes
Agenda & Minutes
Download:
FR
Published: 2018
Author: Haute Autorité de Santé
Update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine
Recommendation
Download:
EN
FR
Published: 2018
Author: NACI
Literature review - Update on immunization in pregnancy with Tdap vaccine
Background paper
Download:
EN
FR
Published: 2018
Author: NACI
What is the risk of other serious adverse events (non-dengue) in seropositive individuals 9-16 years of age vaccinated with CYD-TDV?
GRADE table
Download:
EN
Published: 2018
Author: SAGE
What is the duration of protection/risk in seronegative individuals 9-16 years of age vaccinated with CYD-TDV?
GRADE table
Download:
EN
Published: 2018
Author: SAGE
What is the duration of protection/risk in seropositive individuals 9-16 years of age vaccinated with CYD-TDV?
GRADE table
Download:
EN
Published: 2018
Author: SAGE
What is the efficacy of 3 doses of CYD-TDV in preventing clinical dengue in seronegative individuals 9-16 years of age in the first year following vaccination?
GRADE table
Download:
EN
Published: 2018
Author: SAGE
What is the efficacy of 3 doses of CYD-TDV in preventing clinical dengue in seropositive individuals 9-16 years of age in the first year following vaccination?
GRADE table
Download:
EN
Published: 2018
Author: SAGE
Should countries considering introduction of CYD-TDV to reduce the burden of dengue use a pre-vaccination screening or population seroprevalence based criteria?
Evidence to recommendation table
Download:
EN
Published: 2018
Author: SAGE
Home
Network
Training
Media Center
News
SYSVAC
Events
Sign in / Register